Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.52 |
| ▸ | CTSK | P43235 | 11/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 5/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15549511 | 0.88 | SYK (0.54) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL2131892 | 0.88 | SYK (0.54) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL30680013 | 0.88 | SYK (0.54) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL8728480 | 0.84 | CTSL (0.52) | CTSSCTSKCTSLCTSB | |
| SCHEMBL22356636 | 0.83 | SYK (0.53) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL1262685 | 0.83 | SYK (0.53) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL9180247 | 0.83 | CTSS (0.67) | CTSSCTSKCTSLCTSB | |
| SCHEMBL3817109 | 0.82 | PPARA (0.55) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL1517760 | 0.82 | PPARA (0.55) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL13007476 | 0.82 | PPARA (0.55) | CTSSCTSKCTSLCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | LYCIA THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4359414-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4274619-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | CTSS 446/4885CTSK 936/4885CTSL 932/4885 |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | FOLR1, FOLR2, FOLH1 | CTSS 446/4885CTSK 936/4885CTSL 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.